Finance

Lists
Why is TNGX down 3,42%?
Dive Deeper
TNGX:NASDAQ
Tango Therapeutics Inc
USD 24,85
-3,42%
(-0,88) 1D
USD 24,85
0,00% (0,00)
After hours
Closed: 12 Nov., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNGX...
Open
USD 25,33
High
USD 25,37
Low
USD 23,60
Mkt. cap
4,21 mjd
Avg. vol.
4,21 m
Volume
3,49 m
52-wk high
USD 34,39
52-wk low
USD 7,49
EPS
-USD 1,37
Beta
1,26
Shares outstanding
169,46 m
No. of employees
137
Open
USD 25,33
High
USD 25,37
Low
USD 23,60
Mkt. cap
4,21 mjd
Avg. vol.
4,21 m
Volume
3,49 m
52-wk high
USD 34,39
52-wk low
USD 7,49
EPS
-USD 1,37
Beta
1,26
Shares outstanding
169,46 m
No. of employees
137
News stories
From web sources and news partners
About Tango Therapeutics Inc
CEO-
Employees137
Founded2017
HeadquartersBoston, Massachusetts, Verenigde State van Amerika
SectorHealth Care
Industry-
Websitetangotx.com
Analyst ratings
Based on 7 analysts giving stock ratings to TNGX in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TNGX in the last 3 months.
Highest
Current USD 24,85
USD 67,00 (+169,62%)
Average
USD 45,14 (+81,65%)
Lowest
USD 24,00 (-3,42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
USD 67,00
+169,6%
11/10/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
USD 47,00
+89,1%
11/10/2026
Michael Schmidt
Guggenheim
Buy
Maintained
USD 35,00
+40,8%
11/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
USD 46,00
+85,1%
11/10/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
USD 55,00
+121,3%
10/23/2026
Unknown Analyst
William Blair
Buy
Initiated
USD 42,00
+69%
10/15/2026
Alethia Young
William Blair
Buy
Initiated
USD 42,00
+69%
10/15/2026
Sharon Zackfia
William Blair
Buy
Initiated
USD 42,00
+69%
10/15/2026
Kelsey Goodwin
Piper Sandler
Hold
Maintained
USD 24,00
-3,4%
10/01/2026
Robert Driscoll
Wedbush
Buy
Reiterated
USD 39,00
+56,9%
08/12/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
USD 40,00
+61%
07/17/2026
Maury Raycroft
Jefferies
Buy
Upgraded
USD 60,00
+141,4%
06/26/2026
Kalpit Patel
Wolfe Research
Buy
Upgraded
USD 35,00
+40,8%
06/08/2026
Yuan Zhi
B. Riley Securities
Buy
Reiterated
USD 35,00
+40,8%
06/09/2026
Unknown Analyst
Guggenheim
Buy
Maintained
USD 32,00
+28,8%
06/01/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
USD 55,00
+121,3%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
-
-
-
-
Cost of goods sold
32,10 m
33,53 m
37,20 m
48,93 m
Cost of revenue
32,10 m
33,53 m
37,20 m
48,93 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,76 m
15,24 m
22,59 m
29,19 m
Operating expense
9,76 m
15,24 m
22,59 m
29,19 m
Total operating expenses
41,86 m
48,77 m
59,78 m
78,12 m
Operating income
-41,86 m
-48,77 m
-59,78 m
-78,12 m
Other non operating income
3,30 m
-45,00 k
722,00 k
-29,00 k
EBT including unusual items
-38,80 m
-45,51 m
-55,34 m
-68,39 m
EBT excluding unusual items
-36,88 m
-46,64 m
-55,34 m
-70,99 m
Income tax expense
-55,00 k
1,00 k
1,00 k
-
Effective tax rate
0,14%
-
-
-
Other operating expenses
-
-
-
-
Net income
-38,75 m
-45,51 m
-55,34 m
-68,39 m
Net profit margin
-
-
-
-
Earnings per share
-0,29
-0,32
-0,37
-0,39
Interest and investment income
1,68 m
2,18 m
3,72 m
7,15 m
Interest expense
-
-
-
-
Net interest expenses
1,68 m
2,18 m
3,72 m
7,15 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,38 m
-48,31 m
-59,36 m
-77,70 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme